Examinando por Autor "Aguilar-Aguirre, Isidora"

Mostrando 1 - 3 de 3
  • Miniatura
    Ítem
    A Systematic Review with a Meta-Analysis of the Morphological Variants of the Corpus Callosum: Related Neurocognitive Clinical Implications
    (Elsevier, 2025) Valenzuela Fuenzalida, Juan José; Orellana-Hidalgo, Sebastián; Baeza-Garrido, Vicente; Trujillo-Riveros, Martin; Aguilar-Aguirre, Isidora; Nova-Baeza, Pablo; Orellana-Donoso, Mathias; Cifuentes-Suazo, Gloria; Bruna Mejías, Alejandro; Casanova-Martinez, Daniel; Sanchis-Gimeno, Juan; Piagkou, Maria; Triantafyllou, George; Konschake, Marko
    Background: Corpus callosum agenesis (CCA) occurs in approximately 1 in every 4000 births and is identified in 3–5% of individuals evaluated through neuroimaging for neurodevelopmental disorders. The combined prevalence of CCA and hypoplasia is estimated to range from 1.8 to 10 in every 10,000 births. Methods: The online databases Medline, Scopus, Web of Science, Google Scholar, Cumulative Index to Nursing and Allied Health Literature, and Latin American and Caribbean Literature in Health Sciences were searched until May 2025. Two authors independently conducted the search, selected the studies, and extracted the data. The methodological quality of the studies was assessed using the Anatomical Quality Assessment tool. A random effects model was used to estimate the pooled prevalence. Results: A total of 46 studies met the established selection criteria. In this analysis, 15 articles were included in the meta-analysis, which involved a total of 5,118,037 subjects. The overall prevalence of CCA was 18% (confidence interval = 10%–25%). The subgroup analysis revealed a significant difference in the prevalence of CCA among the Asian continent compared to the other four continents (P-value 0.001). Conclusions: Early diagnosis of CCA during the fetal stage can enable specialists to implement more effective treatments and reduce the likelihood of neurofunctional impairments. Furthermore, understanding the morphological characteristics of CCA can assist in making an early and accurate diagnosis, minimizing the need for differential diagnoses that could interfere with the functioning of the interhemispheric connection system and brain functional connections.
  • Miniatura
    Ítem
    The adverse effects and use of bevacizumab in patients with glioblastoma: a systematic review and meta-analysis
    (MDPI, 2025-05-25) Bruna-Mejías, Alejandro; Silva-Bravo, Vicente; Moyano Valarezo, Laura; Delgado-Retamal, María Fernanda; Nazar-Izquierdo, Diego; Aguilar-Aguirre, Isidora; Nova-Baeza, Pablo; Orellana-Donoso, Mathias; Suazo Santibañez, Alejandra; Gutiérrez-Espinoza, Héctor; Sanchis Gimeno, Juan; Bastidas-Caldes, Carlos; Valenzuela Fuenzalida, Juan José
    A glioblastoma (GBM) is a type of tumor originating from the glial brain cells, the astrocytes, and thus belongs to the astrocytoma group. Bevacizumab (BV) is a treatment for GBM. BV is the active ingredient in the drugs Avastin®, Alymsys®, Mvasi® and ZiraBev®. It is currently approved as second-line treatment for GBM recurrence in combination with radiotherapy, and as first-line treatment for other cancers, including advanced colorectal cancer, metastatic breast cancer and advanced non-small-cell lung cancer. The objective of this systematic review was to analyze the scientific evidence from the science-based literature on the therapeutic effect and adverse effects of the drug BV in patients with GBM or GBM multiforme. Methods: We systematically searched electronic databases for the literature search, including the MEDLINE (via PubMed), SCOPUS, Google Scholar, the Cumulative Index to Nursing and Allied Health Literature and Web of Science databases, covering records from their earliest data to December 2024. Randomized or controlled clinical trials that were published in English or Spanish were included. The following keywords were used in different combinations: “Bevacizumab therapy”, “Bevacizumab pharmaceutical”, “Glioblastoma”, “Glioma” and “multiform glioblastoma”. Results: The use of Bevacizumab has been extensively studied in the scientific literature, with beneficial effects in symptom control. However, the adverse effects of BV vary across different types of carcinomas, which is why it has already been established that these adverse effects must be taken into consideration. In our meta-analysis of adverse effects, we found 14 adverse effects and estimated their prevalence, with an average of 19% (CI: 4 to 44%). The most significant vascular adverse effect was thromboembolism, which led to a greater number of complications for patients with GBM. Finally, the most common adverse effects were nausea, vomiting, fatigue and hypertension. Conclusions: While the beneficial properties of this pharmacological therapy have been observed, its adverse effect profile requires constant evaluation, as it includes vascular, blood and symptomatic adverse effects, which must be analyzed on a case-by-case basis and with great attention, especially in the case of more serious complications such as thromboembolic events.
  • Miniatura
    Ítem
    The Effect of Diabetes Mellitus on Central Corneal Thickness Values: A Systematic Review and Meta-Analysis
    (MDPI, 2025-09-06) Uzunoglu, Arda; Valenzuela Fuenzalida, Juan José; Morales-Calderón, Karin; Aguilar-Aguirre, Isidora; Bruna-Mejías, Alejandro; Nova-Baeza, Pablo; Orellana-Donoso, Mathias; Oyanedel-Amaro, Gustavo; Suazo Santibañez, Alejandra; Sanchis-Gimeno, Juan A.; León Rojas, Jose E.; Granite, Guinevere
    Diabetes mellitus (DM) is a chronic metabolic disorder that can induce systemic and ocular complications. Among the latter, an increase in central corneal thickness (CCT) has been reported, potentially affecting endothelial function and increasing the risk of ocular disease. This study aimed to determine the impact of DM on CCT and to assess its correlation with diabetes duration and glycosylated hemoglobin (HbA1c) levels. A systematic literature search was conducted in Web of Science (1980–2025) following a PICO-based strategy. Observational studies evaluating CCT in diabetic patients were included. Data were analyzed using a random-effects model. Statistical heterogeneity was assessed with χ2 test, p values, and I2 index. Publication bias was evaluated using Begg’s funnel plot and Egger’s regression test. Twenty-nine studies were included in the meta-analysis. Diabetic patients showed significantly higher CCT values compared to controls, particularly in those with long-standing DM (p < 0.001) and poor glycemic control (HbA1c, p < 0.001). Egger’s regression suggested an association between increasing CCT, disease duration, and HbA1c levels, while funnel plot asymmetry indicated potential publication bias. CCT appears to increase in patients with long-term DM and inadequate glycemic control. These findings highlight the relevance of CCT assessment as a potential indicator of corneal changes in diabetic patients.